David Barros

2.3k total citations
22 papers, 870 citations indexed

About

David Barros is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, David Barros has authored 22 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 14 papers in Molecular Biology and 4 papers in Epidemiology. Recurrent topics in David Barros's work include Tuberculosis Research and Epidemiology (15 papers), Biochemical and Molecular Research (7 papers) and Cancer therapeutics and mechanisms (6 papers). David Barros is often cited by papers focused on Tuberculosis Research and Epidemiology (15 papers), Biochemical and Molecular Research (7 papers) and Cancer therapeutics and mechanisms (6 papers). David Barros collaborates with scholars based in Spain, United Kingdom and France. David Barros's co-authors include Lluís Ballell, Gurdyal S. Besra, Jonathan A. G. Cox, Katherine A. Abrahams, Nicholas J. Loman, Carlos Alemparte, Modesto J. Remuiñán, Mark J. Pallen, Raquel M. Fernández and Chrystala Constantinidou and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Medicinal Chemistry.

In The Last Decade

David Barros

22 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Barros Spain 19 478 458 260 198 139 22 870
Marion Flipo France 18 299 0.6× 501 1.1× 158 0.6× 251 1.3× 139 1.0× 30 962
Vinayak Singh South Africa 21 518 1.1× 559 1.2× 250 1.0× 263 1.3× 65 0.5× 51 1.1k
Sun‐Hee Kang South Korea 12 518 1.1× 481 1.1× 311 1.2× 235 1.2× 79 0.6× 24 972
Sreevalli Sharma India 18 533 1.1× 478 1.0× 304 1.2× 238 1.2× 211 1.5× 24 915
Ill Young Lee South Korea 12 454 0.9× 392 0.9× 323 1.2× 311 1.6× 106 0.8× 18 938
Katherine A. Abrahams United Kingdom 12 393 0.8× 410 0.9× 233 0.9× 113 0.6× 77 0.6× 17 629
Cynthia S. Dowd United States 10 817 1.7× 660 1.4× 563 2.2× 213 1.1× 148 1.1× 13 1.3k
Victoria Jones United States 16 589 1.2× 501 1.1× 444 1.7× 221 1.1× 109 0.8× 19 1.0k
Thulasi Warrier United States 15 335 0.7× 284 0.6× 257 1.0× 137 0.7× 97 0.7× 24 647
M.T. Hilgers United States 15 428 0.9× 686 1.5× 77 0.3× 136 0.7× 162 1.2× 17 1.1k

Countries citing papers authored by David Barros

Since Specialization
Citations

This map shows the geographic impact of David Barros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Barros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Barros more than expected).

Fields of papers citing papers by David Barros

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Barros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Barros. The network helps show where David Barros may publish in the future.

Co-authorship network of co-authors of David Barros

This figure shows the co-authorship network connecting the top 25 collaborators of David Barros. A scholar is included among the top collaborators of David Barros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Barros. David Barros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilburn, Kaley M., Christine R. Montague, J.C. Grigg, et al.. (2023). Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. Antimicrobial Agents and Chemotherapy. 67(1). e0129422–e0129422. 18 indexed citations
2.
Boeree, Martin J., et al.. (2021). UNITE4TB: a new consortium for clinical drug and regimen development for TB. The International Journal of Tuberculosis and Lung Disease. 25(11). 886–889. 11 indexed citations
3.
Prati, Federica, Fabio Zuccotto, Daniel A. Fletcher, et al.. (2018). Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. ChemMedChem. 13(7). 672–677. 14 indexed citations
4.
Rogacki, Maciej K., Sophie Huss, Eva María López-Román, et al.. (2018). Identification and Profiling of Hydantoins—A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. Journal of Medicinal Chemistry. 61(24). 11221–11249. 35 indexed citations
5.
Abrahams, Katherine A., Jonathan A. G. Cox, Klaus Fütterer, et al.. (2017). Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface. Scientific Reports. 7(1). 9430–9430. 46 indexed citations
6.
Mugumbate, Grace, V. Mendes, M. Błaszczyk, et al.. (2017). Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. Frontiers in Pharmacology. 8. 681–681. 21 indexed citations
7.
Degiacomi, Giulia, Béatrice Silvia Orena, Giorgia Mori, et al.. (2017). A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. ACS Infectious Diseases. 3(6). 428–437. 28 indexed citations
8.
Pajk, Stane, Roman Šink, Izidor Sosič, et al.. (2016). New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold. European Journal of Medicinal Chemistry. 112. 252–257. 25 indexed citations
9.
Cox, Jonathan A. G., Grace Mugumbate, Monika Jankute, et al.. (2016). Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. Scientific Reports. 6(1). 38986–38986. 22 indexed citations
10.
Ramón‐García, Santiago, Gaye Sweet, Fraser Cunningham, et al.. (2016). Repurposing clinically approved cephalosporins for tuberculosis therapy. Scientific Reports. 6(1). 34293–34293. 57 indexed citations
11.
Mugumbate, Grace, Katherine A. Abrahams, Jonathan A. G. Cox, et al.. (2015). Mycobacterial Dihydrofolate Reductase Inhibitors Identified Using Chemogenomic Methods and In Vitro Validation. PLoS ONE. 10(3). e0121492–e0121492. 34 indexed citations
12.
Sierra-Gallay, I. Li de la, Vincent Dubée, Sébastien Triboulet, et al.. (2015). Hydrolysis of Clavulanate by Mycobacterium tuberculosis β-Lactamase BlaC Harboring a Canonical SDN Motif. Antimicrobial Agents and Chemotherapy. 59(9). 5714–5720. 30 indexed citations
13.
Pérez‐Herrán, Esther, Mónica Cacho, Lluís Ballell, et al.. (2015). Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs. Antimicrobial Agents and Chemotherapy. 59(4). 1868–1875. 39 indexed citations
14.
Gurcha, Sudagar S., Veeraraghavan Usha, Jonathan A. G. Cox, et al.. (2014). Biochemical and Structural Characterization of Mycobacterial Aspartyl-tRNA Synthetase AspS, a Promising TB Drug Target. PLoS ONE. 9(11). e113568–e113568. 26 indexed citations
15.
Šink, Roman, Izidor Sosič, Samo Turk, et al.. (2014). Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis. Journal of Medicinal Chemistry. 58(2). 613–624. 62 indexed citations
16.
Ordas, Anita, Fraser Cunningham, Hans J. Jansen, et al.. (2014). Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen. Antimicrobial Agents and Chemotherapy. 59(2). 753–762. 51 indexed citations
17.
Xia, Xin, Kévin Pethe, Lluís Ballell, et al.. (2014). Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities. Nanomaterials. 4(3). 813–826. 19 indexed citations
18.
Abrahams, Katherine A., Jonathan A. G. Cox, Nicholas J. Loman, et al.. (2012). Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB. PLoS ONE. 7(12). e52951–e52951. 139 indexed citations
19.
Escribano, Jaime, David Barros, Julia Castro‐Pichel, et al.. (2011). 4‐Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween‐80 in vitro Dependent Families of Antitubercular Agents with Moderate in vivo Activity. ChemMedChem. 6(12). 2252–2263. 21 indexed citations
20.
Vivas, Livia, Anna Easton, Howard Kendrick, et al.. (2005). Plasmodium falciparum: Stage specific effects of a selective inhibitor of lactate dehydrogenase. Experimental Parasitology. 111(2). 105–114. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marion Flipo Breakdown of academic impact, for papers by Vinayak Singh Breakdown of academic impact, for papers by Sun‐Hee Kang Breakdown of academic impact, for papers by Sreevalli Sharma Breakdown of academic impact, for papers by Ill Young Lee Breakdown of academic impact, for papers by Katherine A. Abrahams Breakdown of academic impact, for papers by Cynthia S. Dowd Breakdown of academic impact, for papers by Victoria Jones Breakdown of academic impact, for papers by Thulasi Warrier Breakdown of academic impact, for papers by M.T. Hilgers
Rankless by CCL
2026